TY  - JOUR
T1  - NEw findings challenge thinking about anemia, iron deficiency, and heart risk
AU  - Mitka M
Y1  - 2010/02/03
N1  - 10.1001/jama.2010.37
JO  - JAMA
SP  - 405
EP  - 406
VL  - 303
IS  - 5
N2  - 
Anemia serves as a biomarker because lower hemoglobin levels are associated with higher rates of cardiovascular and renal events. One treatment strategy is to use erythropoiesis-stimulating agents (ESAs) to increase hemoglobin levels. ESAs have been found to reduce the need for red-cell transfusions and improve such patient quality-of-life factors as fatigue. But until lately, ESAs had not been tested against a placebo, so their effects on hard clinical end points such as reducing the risk of a cardiovascular event or death had remained unknown.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.37
UR  - http://dx.doi.org/10.1001/jama.2010.37
ER  -